ZBH

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2001, for Zimmer Holdings, Inc. (Zimmer). At the time of filing, Zimmer was a wholly-owned subsidiary of Bristol-Myers Squibb (BMS) in the process of a tax-free spin-off. The financial statements reflect Zimmer's operations as a distinct business unit prior to the distribution of shares to BMS stockholders on August 6, 2001. Zimmer designs, develops, manufactures, and markets orthopaedic reconstructive implants, fracture management products, and surgical products.

Key Financial Metrics

Note: As a subsidiary, Zimmer had no independent long-term debt on its historical balance sheet; obligations to BMS were reported as "Due to Bristol-Myers Squibb" ($155.4 million) and "Net Investment in Zimmer by Bristol-Myers Squibb" ($235.4 million).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13% year-over-year for both the quarter and the six-month period. Growth was driven by a 14-15% increase in volume and product mix, partially offset by a 4% negative impact from foreign exchange rates.
• Profitability: Reported operating profit decreased 4% year-over-year ($68.9M vs. $71.9M for the quarter; $125.5M vs. $130.7M for six months). However, excluding separation costs, operating profit increased 14% for the quarter and 17% for the six months.
• Expense Increases: General and administrative expenses rose significantly (33% for the quarter, 9% for six months) due to information technology initiatives and separation-related costs. Research and development spending increased 43% for the six months to support new product development.
• Segment Performance: The Americas region led growth with a 21% sales increase. Asia Pacific sales declined 5% (quarter) and 3% (six months) primarily due to foreign exchange fluctuations, though volume increased.

Outlook, Risks, and Unusual Items

• Separation Costs: The company incurred $13.1 million in separation costs for the quarter and $27.5 million for the six months. Total estimated separation costs are approximately $70 million ($50 million net of tax).
• Debt Assumption: Upon separation, Zimmer assumed or will incur approximately $450 million in debt under a new $600 million senior unsecured credit facility. Pro forma interest expense is estimated at $12.5 million for the six-month period.
• Pro Forma Results: Adjusted for the debt assumption and separation costs, pro forma net earnings for the six months ended June 30, 2001, would be $71.4 million ($0.37 per share diluted), compared to historical net earnings of $79.2 million.
• Risks: Key risks include foreign exchange rate fluctuations, product liability claims (though management does not expect material adverse effects), and the successful execution of the spin-off transaction.

Investor Verification Checklist

• Spin-off Mechanics: Verify the final terms of the distribution of Zimmer stock to Bristol-Myers Squibb shareholders and the tax-free status of the transaction.
• Debt Structure: Confirm the final amount of debt drawn under the $600 million credit facility and the associated interest rate covenants.
• Separation Costs: Monitor the final realization of the estimated $70 million in separation costs and any potential overruns.
• Foreign Exchange Exposure: Assess the impact of currency fluctuations on future earnings, given the significant negative impact observed in the Asia Pacific region.
• Pro Forma Adjustments: Review the unaudited pro forma financial statements to understand the standalone capital structure and leverage ratios post-separation.